Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension
- 1 October 2003
- Vol. 124 (4) , 1294-1304
- https://doi.org/10.1378/chest.124.4.1294
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin AnalogueNew England Journal of Medicine, 2000
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled TrialAnnals of Internal Medicine, 2000
- Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 1999
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.American Journal of Respiratory and Critical Care Medicine, 1995
- Aerosolised prostacyclin in adult respiratory distress syndromeThe Lancet, 1993
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991
- Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in manEuropean Journal of Clinical Pharmacology, 1986